Ginkgo Bioworks Holdings Inc - 2025年季度报告

FORM10-Q oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _________________ to _________________ GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) 02210(Zip Code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days.Yesx Noo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yesx Noo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and As of April 30, 2025, the registrant had46,344,630shares of Class A common stock,9,187,247shares of Class B common stock, and3,000,000shares of non-voting Class C common stock outstanding. Cautionary Note Regarding Forward Looking Statements This report includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business andfinancial, of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”). These statements are based on the beliefs andassumptions of the management of Ginkgo. Although Ginkgo believes that its plans, intentions and expectations reflected in orsuggested by these forward-looking statements are reasonable, Ginkgo cannot assure you that it will achieve or realize these plans,intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally,statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events •Ginkgo’s ability to raise additional capital in the future •factors relating to the business, operations and financial performance of Ginkgo, including: Ginkgo’s ability to develop and expand its offerings;the performance and output of Ginkgo’s cell engineering and biosecurity offerings;the anticipated growth of Ginkgo’s biomonitoring and bioinformatics services and the relative value of the serviceson Ginkgo’s future Biosecurity revenue;the scope and timing of Ginkgo’s partnerships around the world; Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from thoseexpressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others: •intense competition and competitive pressures from other companies worldwide in the industries in which Ginkgo operates;•litigation, including securities or shareholder litigation, and the ability to adequately protect Ginkgo’s intellectual propertyrights;•rapidly changing technology and extensive competition in the synthetic biology industry that could make the products and •Ginkgo’s ability to comply with laws and regulations applicable to its business; •market conditions and global and economic factors beyond Ginkgo’s control, including initiatives undertaken by the U.S.government in the biotechnology sector, the frequency and scale of biological risks and threats, and the future potential and •the success of Ginkgo’s programs, including the growing efficiency and cost-advantage of cell engineering services, and theirpotential to contribute revenue, and the relative contribution of Ginkgo’s programs to its future revenue, including the •other factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with theSEC on February 25, 2025 (“2024 Annual Report”). These and other factors that could cause actual results to differ from those implied by the forward-looking statements in this QuarterlyReport on Form 10-Q are more fully described under the heading “Risk Factors” in the 2024 Annual Report and elsewhere in thisreport, which are not exhaustive. Other sections of this Quarterly Report on Form 10-Q describe additional factors that could adverselyaffect the business, financial condition or results of Ginkgo. New risk factors emerge from time to time and it is not possible to predictall such risk factors, nor can Ginkgo assess the impact of all such risk factors on the business of Ginkgo, or the extent to which any Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive Loss PART I—FINANCIAL INFORMATION Ginkgo Bioworks Holdings